arrow
S

Sudarshan Sharma

department of obstetrics/gynecology, amita health adventist medical center, hinsdale, il, usa
H指数:20
被引数:4,779

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

一份关于接受多塔利单抗联合卡铂-紫杉醇治疗子宫内膜癌患者生存情况的通俗语言摘要出版物

2025-10-090
OA
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial

在预后不良的卵巢癌中,添加免疫检查点抑制剂atezolizumab到一线化疗对无进展生存期的影响:IMagyn050试验的一项回顾性分析

2025-06-010
OAAI
Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up

ENGOT-EN6-NSGO/GOG3031/RUBY试验中,接受化疗联合Dostarlimab或安慰剂治疗的原发性晚期或复发性子宫内膜癌患者三年随访的结局报告

2025-02-010
PRE
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

多塔利单抗联合化疗在dMMR/MSI-H原发性晚期或复发性子宫内膜癌患者中的有效性和安全性:一项III期、随机、安慰剂对照试验(ENGOT-EN6-NSGO/GOG-3031/RUBY)。

2025-01-014
PRE
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
2024-09-280
OAAI
A Plain Language Summary of Dostarlimab for primary advanced or recurrent endometrial cancer
2024-07-010
PRE
Dostarlimab plus chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
2023-10-0114
PRE
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
2023-06-08294
OA
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
2021-03-178
OAAI